Stock market data from financial platforms such as Bloomberg or Yahoo Finance

Amgen and AstraZeneca Report Positive Phase 3 WAYPOINT Results for Tezspire in CRSwNP, Meeting Primary Endpoints

Nov 8, 2024, 07:11 AM

Amgen and AstraZeneca have announced positive top-line results from their Phase 3 WAYPOINT trial evaluating Tezspire for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP). The trial met both co-primary endpoints, demonstrating a statistically significant reduction in nasal polyp size. This marks a significant advancement in treatment options for patients suffering from this condition. The companies' stocks, $AMGN and $AZN, are likely to be impacted by this development.